Medistim ASA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

A week ago, Medistim ASA (OB:MEDI) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. It was a solid earnings report, with revenues and statutory earnings per share (EPS) both coming in strong. Revenues were 13% higher than the analysts had forecast, at kr210m, while EPS were kr2.61 beating analyst models by 25%. Earnings are an important time for investors, as they can track a company’s performance, look at what the analysts are forecasting for next year, and see if there’s been a change in sentiment towards the company. We’ve gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

We’ve found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the consensus forecast from Medistim’s two analysts is for revenues of kr938.0m in 2027. This reflects a meaningful 18% improvement in revenue compared to the last 12 months. In the lead-up to this report, the analysts had been modelling revenues of kr867.5m and earnings per share (EPS) of kr10.80 in 2027. What’s really interesting is that while the consensus made a slight bump in revenue estimates, it no longer provides an earnings per share estimate. This suggests that revenues are now the focus of the business after this latest result.

See our latest analysis for Medistim

Additionally, the consensus price target for Medistim rose 9.8% to kr365, showing a clear increase in optimism from the the analysts involved.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The period to the end of 2027 brings more of the same, according to the analysts, with revenue forecast to display 14% growth on an annualised basis. That is in line with its 13% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 6.9% per year. So although Medistim is expected to maintain its revenue growth rate, it’s definitely expected to grow faster than the wider industry.

The Bottom Line

The highlight for us was that the analysts increased their revenue forecasts for Medistim next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

We have estimates for Medistim from its two analysts out to 2028, and you can see them free on our platform here.

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.